REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)
A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)
Sponsor: Stem Cell Therapeutics Corp.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Stem Cell Therapeutics Corp.
More terminations from Stem Cell Therapeutics Corp.
Listed as NCT00663416, this PHASE2 trial focuses on Stroke and remains terminated or withdrawn. Sponsored by Stem Cell Therapeutics Corp., it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stem Cell Therapeutics Corp.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangalore, India , Brandon, Canada , Calgary, Canada , Edmonton, Canada , Halifax, Canada , Hamilton, Canada , Hyderabad, India , Kolkata, India , Lethbridge, Canada , Ludhiana, India and 9 more locations